Researchers identify drug target to reduce brain inflammation

Targeting a brain receptor known as P2X7 significantly reduced inflammation in human brain tissue, ScienceDaily reported on October 7, 2026. The findings could allow medical researchers to repurpose existing medications to treat several neurological and psychiatric disorders. [1]

The research team was led by Professor Nicholas Barnes at the University of Birmingham and published their findings in the journal Brain, according to ScienceDaily. The study indicates that blocking the P2X7 receptor may help manage conditions such as traumatic brain injury, depression, and schizophrenia. [1]

The discovery also holds promise for neurodegenerative conditions including Alzheimer's disease and Parkinson's disease. Alzheimer's disease is a neurodegenerative disorder that represents 60 to 70 percent of dementia cases, causing progressive memory loss and cognitive decline. [1][2]

Because existing drugs can already block the P2X7 receptor, scientists hope the strategy will accelerate the development of new therapies for patients. ScienceDaily reported that targeting this specific receptor provides a novel approach to mitigating harmful inflammation in the brain. [1]